{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:30:37Z","timestamp":1770276637191,"version":"3.49.0"},"reference-count":23,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Given the limited availability of real world diffuse large B-cell lymphoma (DLBCL) data in Germany, we assessed the baseline characteristics, treatments, clinical complications, healthcare resource utilization and costs of DLBCL across treatment lines using German claims data.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            In a retrospective cohort study using claims data from a German sickness fund (AOK PLUS), we identified patients with an incident DLBCL diagnosis between 2012 and 2022. Using an algorithm based on German treatment guidelines, patients were stratified into first (1L), second (2L) and third line (3L) treatment. We then descriptively analyzed baseline characteristics, treatments, clinical complications, healthcare resource utilization and costs.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 2423 patients with DLBCL and 1L treatment were included in the study (49.1% female; mean age: 69.7 years; mean CCI: 7.0; median follow-up: 29.3\u00a0months). A total of 1209 (49.7%) and 505 (20.8%) patients progressed to 2L and 3L, respectively. A total of 209 patients received a stem cell transplant (SCT; mean age: 56.1\u00a0years); 37 received a chimeric antigen receptor T-cell therapy (CAR-T; mean age: 60.8\u00a0years). Most patients had at least one DLBCL related hospitalization during follow-up (1L: 79.2%; 2L: 60.0%; 3L: 71.9%; mean length of stay [days\/patient year]: 1L: 15.2; 2L: 6.4; 3L: 14.2), with corresponding hospitalization costs of 12,777\u20ac (1L), 5993\u20ac (2L) and 17,408\u20ac (3L) per patient year. Clinical complications were common, particularly in 3L, including neutropenia (1L: 31.9%; 2L: 27.0%; 3L: 46.9%), pneumonia (1L: 19.6%; 2L: 16.8%; 3L: 30.3%), anemia (1L: 17.8%; 2L: 18.7%; 3L: 35.2%), thrombocytopenia (1L: 17.3%; 2L: 21.8%; 3L: 45.1%) and sepsis (1L: 14.6%; 2L: 13.0%; 3L: 23.2%).\n            <jats:bold>Conclusion:<\/jats:bold>\n            The high proportion of patients with second or later-line treatment (indicating a relapse or refractory disease), the low number of SCTs together with many clinical complications and healthcare resource use underscore the need for novel effective and well-tolerated DLBCL treatment options.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0218","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:59:14Z","timestamp":1755093554000},"source":"Crossref","is-referenced-by-count":1,"title":["Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma \u2013 a German claims data study"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-163X","authenticated-orcid":false,"given":"Katja","family":"Greth","sequence":"first","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ghiani","sequence":"additional","affiliation":[{"name":"Cytel Inc., Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik e.V. (IPAM), Wismar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Russell","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd, Sandwich, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mugdha","family":"Gokhale","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"5","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu Y","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 94(5), 604\u2013616 (2019).","journal-title":"Am. J. Hematol."},{"issue":"6","key":"e_1_3_8_4_2","first-page":"366","article-title":"Relapsed or refractory diffuse large B-cell lymphoma: \u201cdazed and confused\u201d","volume":"36","author":"Kesireddy M","year":"2022","unstructured":"Kesireddy M, Lunning M. Relapsed or refractory diffuse large B-cell lymphoma: \u201cdazed and confused\u201d. Oncology (Williston Park) 36(6), 366\u2013375 (2022).","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41416-021-01525-4","article-title":"Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year real world data of practice patterns and outcomes in England","volume":"126","author":"Hounsome L","year":"2022","unstructured":"Hounsome L, Eyre TA, Ireland R Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year real world data of practice patterns and outcomes in England. Br. J. Cancer 126(1), 134\u2013143 (2022).","journal-title":"Br. J. Cancer"},{"key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"824704","DOI":"10.3389\/fonc.2022.824704","article-title":"Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study","volume":"12","author":"Daneels W","year":"2022","unstructured":"Daneels W, Rosskamp M, Macq G Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study. Front. Oncol. 12, 824704 (2022).","journal-title":"Front. Oncol."},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13721"},{"key":"e_1_3_8_8_2","unstructured":"SEER cancer stat facts: NHL \u2013 diffuse large B-cell lymphoma (DLBCL). National Cancer Institute MD USA. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-024-00265-8"},{"key":"e_1_3_8_10_2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK AWMF). Diagnostik Therapie und Nachsorge f\u00fcr erwachsene Patient*innen mit einem diffusen gro\u00dfzelligen B-Zell-Lymphom und verwandten Entit\u00e4ten Langversion 1.0. (2022)."},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00211-6"},{"issue":"9","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison VA","year":"2019","unstructured":"Morrison VA, Shou Y, Bell JA Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 15(9), 1021\u20131034 (2019).","journal-title":"Future Oncol."},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0094"},{"issue":"10","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1007\/s00432-023-04660-y","article-title":"Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database","volume":"149","author":"Borchmann P","year":"2023","unstructured":"Borchmann P, Heger JM, Mahlich J Survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma: real-world evidence from a German claims database. J. Cancer Res. Clin. Oncol. 149(10), 7091\u20137101 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"e_1_3_8_15_2","volume-title":"Diffuses gro\u00dfzelliges B-Zell-Lymphom","author":"D\u00fchrsen U","year":"2018","unstructured":"D\u00fchrsen U, Fridrik MA, Klapper W, Schmitz N. Diffuses gro\u00dfzelliges B-Zell-Lymphom. Berlin, Germany (2018)."},{"key":"e_1_3_8_16_2","volume-title":"Diffuses gro\u00dfzelliges B-Zell-Lymphom","author":"D\u00fchrsen U","year":"2014","unstructured":"D\u00fchrsen U, Fridrik MA, Schmitz N. Diffuses gro\u00dfzelliges B-Zell-Lymphom. Berlin, Germany (2014)."},{"issue":"13","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1080\/10428194.2019.1623886","article-title":"Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database","volume":"60","author":"Shaw J","year":"2019","unstructured":"Shaw J, Harvey C, Richards C, Kim C. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database. Leuk. Lymphoma 60(13), 3235\u20133243 (2019).","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"e7173","DOI":"10.1002\/cam4.7173","article-title":"Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy","volume":"13","author":"Sineshaw HM","year":"2024","unstructured":"Sineshaw HM, Zettler CM, Prescott J Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy. Cancer Med. 13(7), e7173 (2024).","journal-title":"Cancer Med."},{"key":"e_1_3_8_19_2","unstructured":"DRST Deutsches Register f\u00fcr Stammzelltransplantationen e.V. Jahresbericht 2022. Ulm Germany (2022)."},{"key":"e_1_3_8_20_2","unstructured":"Georg Lenz BC Bertram Gla\u00df Felix Keil Diffuses gro\u00dfzelliges B-Zell-Lymphom. Onkopedia Leitlinie: DGHO OeGHO SGHSSH SSMO (2021)."},{"key":"e_1_3_8_21_2","unstructured":"Pharmazeutische Zeitung. Arzneistoffe: Avoxa - Mediengruppe Deutscher Apotheker GmbH (2024). Available from: https:\/\/www.pharmazeutische-zeitung.de\/arzneistoff-wirkstoff\/"},{"issue":"7","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clml.2021.12.018","article-title":"Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective","volume":"22","author":"Moertl B","year":"2022","unstructured":"Moertl B, Dreyling M, Schmidt C Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): a health economic perspective. Clin. Lymphoma Myeloma Leuk. 22(7), 474\u2013482 (2022).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2349472"},{"issue":"5","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"e0269169","DOI":"10.1371\/journal.pone.0269169","article-title":"Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis","volume":"17","author":"Tsutsu\u00e9 S","year":"2022","unstructured":"Tsutsu\u00e9 S, Makita S, Yi J, Crawford B. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis. PLoS ONE 17(5), e0269169 (2022).","journal-title":"PLoS ONE"},{"issue":"12","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier B","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116(12), 2040\u20132045 (2010).","journal-title":"Blood"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:53:41Z","timestamp":1756457621000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2024-0218"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0218","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e240218"}}